An additional autologous anti-CD19 CAR T-cell therapy was FDA-approved in October 2017, i.e., axicabtagene ciloleucel (axi-cel, YESCARTA®, Kite Pharma Inc.)for adult patients with R/R DLBCL, primary mediastinal large B-cell lymphoma (PMBCL), high grade B-cell lymphoma and transformed FL. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.